Market Research Logo

Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022

Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022

About Non-alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease is a condition in which excess fat is stored in the liver. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver cell damage.

Technavio’s analysts forecast the Global Non-alcoholic Fatty Liver Disease Therapeutics Market to grow at a CAGR of 16.19% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the non-alcoholic fatty liver disease therapeutics market. To calculate the market size, the report considers the revenue generated by the applications of non-alcoholic fatty liver disease therapeutics across the globe.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, non-alcoholic fatty liver disease therapeutics market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • ALLERGAN
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
Market driver
  • Increasing prevalence of non-alcoholic fatty liver disease
  • For a full, detailed list, view our report
Market challenge
  • Unclear pathogenesis of non-alcoholic fatty liver disease
  • For a full, detailed list, view our report
Market trend
  • Growing number of strategic alliances
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


PRESS RELEASE

Technavio Announces the Publication of its Research Report - Global Non-alcoholic Fatty Liver Disease Therapeutics Market 2018-2022

Technavio recognizes the following companies as the key players in the global non-alcoholic fatty liver disease therapeutics market: ALLERGAN, GlaxoSmithKline, Merck, Novartis, and Pfizer.

Commenting on the report, an analyst from Technavio’s team said: “One trend affecting this market is the growing number of strategic alliances. Vendors in the global non-alcoholic fatty liver disease therapeutics market are regularly engaging in strategic alliances to consolidate their market position.”

According to the report, one driver influencing this market is the increasing prevalence of non-alcoholic fatty liver disease. The global non-alcoholic fatty liver disease therapeutics is expected to grow during the forecast period owing to growing incidences of non-alcoholic fatty liver diseases across the globe.

Further, the report states that one challenge affecting this market is the unclear pathogenesis of non-alcoholic fatty liver disease. One of the main drawbacks of the assessment and treatment of non-alcoholic fatty liver disease is the lack of accurate noninvasive diagnostic methods.

Companies Mentioned

ALLERGAN
GlaxoSmithKline
Merck
Novartis
Pfizer

  • Executive summary
  • Scope of the report
  • Research methodology
  • Market landscape
    • Market ecosystem
      • Table Parent market
      • Table Global metabolic disorders therapeutics market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition: Inclusions and exclusions checklist
    • Market sizing 2017
      • Table Market size 2017
      • Table Validation techniques employed for market sizing 2017
    • Market size and forecast
      • Table Global NAFLD therapeutics market – Market size and forecast 2017-2022 ($ mn)
      • Table Global NAFLD therapeutics market – Year-over-year growth 2018-2022 (%)
  • Five forces analysis
    • Table Five forces analysis 2017
    • Table Five forces analysis 2022
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition: Five forces 2017
  • Pipeline landscape
    • Table Pipeline landscape by development phase 2017-2018
    • Table Late-stage pipeline molecules for the treatment of NAFLD 2017-2018
  • Market segmentation by RoA
    • Segmentation by RoA
      • Table Global NAFLD therapeutics market – Market share by RoA 2017-2022 (%)
    • Comparison by RoA
      • Table Comparison by RoA
    • Oral RoA – Market size and forecast 2017-2022
      • Table Global NAFLD therapeutics market by oral RoA – Market size and forecast 2017-2022 ($ mn)
      • Table Global NAFLD therapeutics market by oral RoA – Year-over-year growth 2018-2022 (%)
    • Parenteral RoA – Market size and forecast 2017- 2022
      • Table Global NAFLD therapeutics market by parenteral RoA – Market size and forecast 2017- 2022 ($ mn)
      • Table Global NAFLD therapeutics market by parenteral RoA – Year-over-year growth 2018- 2022 (%)
    • Market opportunity by RoA
      • Table Market opportunity by RoA
  • Customer landscape
    • Table Customer landscape
  • Regional landscape
    • Geographical segmentation
      • Table Global NAFLD therapeutics market by geography – Market share 2017-2022 (%)
    • Regional comparison
      • Table Regional comparison
    • NAFLD therapeutics market in the Americas – Market size and forecast 2017-2022
      • Table NAFLD therapeutics market in Americas – Market size and forecast 2017-2022 ($ mn)
      • Table NAFLD therapeutics market in Americas – Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in Americas
    • NAFLD therapeutics market in EMEA – Market size and forecast 2017-2022
      • Table NAFLD therapeutics market in EMEA – Market size and forecast 2017-2022 ($ mn)
      • Table NAFLD therapeutics market in EMEA – Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in EMEA
    • NAFLD therapeutics market in APAC – Market size and forecast 2017-2022
      • Table NAFLD therapeutics market in APAC – Market size and forecast 2017-2022 ($ mn)
      • Table NAFLD therapeutics market in APAC – Year-over-year growth 2018-2022 (%)
      • Table Top 3 countries in APAC
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • ALLERGAN
      • Table ALLERGAN: Overview
      • Table ALLERGAN – Business segments
      • Table ALLERGAN – Organizational developments
      • Table ALLERGAN – Geographic focus
      • Table ALLERGAN – Segment focus
      • Table ALLERGAN – Key offerings
      • Table ALLERGAN – Key customers
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Overview
      • Table GlaxoSmithKline – Business segments
      • Table GlaxoSmithKline – Organizational developments
      • Table GlaxoSmithKline – Geographic focus
      • Table GlaxoSmithKline – Segment focus
      • Table GlaxoSmithKline – Key offerings
      • Table GlaxoSmithKline – Key customers
    • Merck
      • Table Merck– Overview
      • Table Merck– Business segments
      • Table Merck– Organizational developments
      • Table Merck– Geographic focus
      • Table Merck– Segment focus
      • Table Merck– Key offerings
      • Table Merck– Key customers
    • Novartis
      • Table Novartis – Overview
      • Table Novartis – Business segments
      • Table Novartis – Organizational developments
      • Table Novartis – Geographic focus
      • Table Novartis – Segment focus
      • Table Novartis – Key offerings
      • Table Novartis – Key customers
    • Pfizer
      • Table Pfizer: Overview
      • Table Pfizer – Business segments
      • Table Pfizer – Organizational developments
      • Table Pfizer – Geographic focus
      • Table Pfizer – Segment focus
      • Table Pfizer – Key offerings
      • Table Pfizer – Key customers
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report